Overactivation of S6 Kinase 1 as a Cause of Human Insulin Resistance During Increased Amino Acid Availability

Overactivation of S6 Kinase 1 as a Cause of Human Insulin Resistance During Increased Amino Acid Availability Frédéric Tremblay 1 , Michael Krebs 2 , Luce Dombrowski 1 , Attila Brehm 2 , Elisabeth Bernroider 2 , Erich Roth 3 , Peter Nowotny 2 , Werner Waldhäusl 2 , André Marette 1 and Michael Roden...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2005-09, Vol.54 (9), p.2674-2684
Hauptverfasser: TREMBLAY, Frédérie, KREBS, Michael, DOMBROWSKI, Luce, BREHM, Attila, BERNROIDER, Elisabeth, ROTH, Erich, NOWOTNY, Peter, WALDHHUSL, Werner, MARETTE, Andre, RODEN, Michael
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Overactivation of S6 Kinase 1 as a Cause of Human Insulin Resistance During Increased Amino Acid Availability Frédéric Tremblay 1 , Michael Krebs 2 , Luce Dombrowski 1 , Attila Brehm 2 , Elisabeth Bernroider 2 , Erich Roth 3 , Peter Nowotny 2 , Werner Waldhäusl 2 , André Marette 1 and Michael Roden 2 4 1 Department of Physiology and Lipid Research Unit, Laval University Hospital Research Center, Ste-Foy, Québec, Canada 2 Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria 3 Department of Surgery, Medical University of Vienna,Vienna, Austria 4 1. Medical Department, Hanusch Hospital, Vienna, Austria Address correspondencereprint requests to Michael Roden, MD, Department of Internal Medicine III, Währinger Gürtel 18–20, A-1090 Vienna, Austria. E-mail: michael.roden{at}meduniwien.ac.at . Or André Marette, PhD, Lipid Research Unit, CHUL Research Center, Ste-Foy, Québec, G1V 4G2, Canada. E-mail: andre.marette{at}crchul.ulaval.ca Abstract To examine the molecular mechanisms by which plasma amino acid elevation impairs insulin action, we studied seven healthy men twice in random order during infusion of an amino acid mixture or saline (total plasma amino acid ∼6 vs. ∼2 mmol/l). Somatostatin-insulin-glucose clamps created conditions of low peripheral hyperinsulinemia (∼100 pmol/l, 0–180 min) and prandial-like peripheral hyperinsulinemia (∼430 pmol/l, 180–360 min). At low peripheral hyperinsulinemia, endogenous glucose production (EGP) did not change during amino acid infusion but decreased by ∼70% during saline infusion (EGP 150–180 min 11 ± 1 vs. 3 ± 1 μmol · kg −1 · min −1 , P = 0.001). Prandial-like peripheral hyperinsulinemia completely suppressed EGP during both protocols, whereas whole-body rate of glucose disappearance ( R d ) was ∼33% lower during amino acid infusion ( R d 330–360 min 50 ± 4 vs. 75 ± 6 μmol · kg −1 · min −1 , P = 0.002) indicating insulin resistance. In skeletal muscle biopsies taken before and after prandial-like peripheral hyperinsulinemia, plasma amino acid elevation markedly increased the ability of insulin to activate S6 kinase 1 compared with saline infusion (∼3.7- vs. ∼1.9-fold over baseline). Furthermore, amino acid infusion increased the inhibitory insulin receptor substrate-1 phosphorylation at Ser312 and Ser636/639 and decreased insulin-induced phosphoinositide 3-kinase activity. However, plasma amino acid elevation failed to reduce insulin-induced Akt/prot
ISSN:0012-1797
1939-327X
DOI:10.2337/diabetes.54.9.2674